文献速递血液净化与透析肾血管病与高血压

β受体阻滞剂联合肾素-血管紧张素系统阻滞剂可改善新发血液透析患者的生存

The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study.
PubMed 文献 · Kidney Int Rep · 2017-03-07

本研究为倾向性评分匹配研究,纳入西班牙2518例新发血液透析患者,比较不同类别降压药对心血管死亡率的影响。中位随访2.21年,校正基线心血管风险协变量后,RAS阻滞剂与β受体阻滞剂单药治疗间心血管死亡率无显著差异,但两者联合较任一单药或其它降压药均与更优的心血管生存相关。

要点

  • RAS阻滞剂联合β受体阻滞剂较单药或其它降压药与更优心血管生存相关。
  • RAS阻滞剂与β受体阻滞剂单药治疗间心血管死亡率无显著差异。
  • 该联合方案的获益需前瞻性随机对照试验进一步确认。

核心结论

  • RAS阻滞剂与β受体阻滞剂联合可能改善血液透析患者生存。

研究设计与样本

  • 倾向性评分匹配研究,纳入西班牙2518例新发血液透析患者,随访最长5年(中位2.21年,范围1.04-3.34年)。

主要发现

  • 校正基线心血管风险协变量后,RAS阻滞剂与β受体阻滞剂单药治疗间心血管死亡率无显著差异。
  • 联合治疗较RAS阻滞剂单药的心血管死亡HR为1.68(95%CI 1.05-2.69)。
  • 联合治疗较β受体阻滞剂单药的心血管死亡HR为1.59(95%CI 1.01-2.50)。
  • 联合治疗较其它降压药的心血管死亡HR为1.67(95%CI 1.08-2.58)。

临床怎么用

  • 在新发血液透析高血压患者中,可考虑RAS阻滞剂与β受体阻滞剂联合以改善心血管生存。

局限性

  • 研究为观察性设计,需前瞻性随机对照试验确认联合方案的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although several studies suggest that the prognosis of hypertensive dialysis patients can be improved by using antihypertensive drug therapy, it is unknown whether the prescription of a particular class or combination of antihypertensive drugs is beneficial during hemodialysis. METHODS: We performed a propensity score matching study to compare the effectiveness of various classes of antihypertensive drugs on cardiovascular (CV) mortality in 2518 incident hemodialysis patients in Spain. The patients had initially received antihypertensive therapy with a renin-angiotensin system (RAS) blocker (728 patients), a ß-blocker (679 patients), antihypertensive drugs other than a RAS blocker or a ß-blocker (787 patients), or the combination of a ß-blocker and a RAS inhibitor (324 patients). These patients were followed for a maximum of 5 years (median: 2.21 yr; range: 1.04-3.34 yr). RESULTS: After adjustment for baseline CV risk covariates, no significant differences were observed in the risk of CV mortality between patients taking a RAS blocker and patients treated with ß-blocker-based antihypertensive therapy. The combination of a RAS blocker with a ß-blocker was associated with better CV survival than either agent alone (RAS blocker: hazard ratio [HR]: 1.68; 95% confidence interval [CI] 1.05-2.69; ß-blocker: HR: 1.59; 95% CI: 1.01-2.50; antihypertensive medication other than a RAS blocker or ß-blocker: HR: 1.67; 95% CI: 1.08-2.58). DISCUSSION: Our data suggested that the combination of a RAS blocker and a ß-blocker could improve survival in hemodialysis patients. Further prospective randomized controlled trials are necessary to confirm the beneficial effects of this combination of antihypertensive drugs in patients undergoing hemodialysis.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Luño J, Varas J, Ramos R, et al. The Combination of Beta Blockers and Renin-Angiotensin System Blockers Improves Survival in Incident Hemodialysis Patients: A Propensity-Matched Study. Kidney Int Rep. 2017. PMID: 29142984. doi:10.1016/j.ekir.2017.03.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。